Our team is interested in the antitumor immune response. T cell lymphocytes are key cells in tumor control. We seek to identify tumor antigens recognized by both CD4 and CD8 T cells. We focus on tumor antigens expressed by therapeutic resistantes tumror cells and evaluate the potential of telomerase derived paptides in cancer immunotherapies. We use several approaches from transcriptomic analysis to experimental animal models. We are also implied in the development of both adoptive immunotherapies using NK and T cells and active immunotherapies using peptides and DNA.